Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

QLT completes phase Ia safety trial of QLT-091001 in healthy volunteers

March 13, 2009

Sunesis sells LFA-1 inhibitor program to SARcode for USD 2 million

March 11, 2009

Opko terminates phase III bevasiranib trial for wet AMD

March 9, 2009

ThromboGenics completes patient enrollment for phase II microplasmin trial

March 9, 2009

EyeGate completes phase II EGP-437 trial for dry eye syndrome

March 5, 2009

Antibody fragment ESBA-105 enters phase IIa studies for uveitis

Feb. 25, 2009

Kyowa Hakko Kirin reports prostanoid FP receptor agonists with antiglaucoma properties

Feb. 23, 2009

Arana discontinues PMX-53 development for ocular indications

Feb. 20, 2009

New ocular hypotensive agents for glaucoma imparted in recent Pfizer patent

Feb. 19, 2009

Lux Biosciences initiates LX-214 study for dry eye syndrome

Feb. 18, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...